Such funds have been given two alternatives by the regulator: one, they could sell the illiquid investments to a new scheme within the same AIF; two, they could do what is called in-specie distribution where the fund transfers shares or securities to each investor based on their unitholding.
Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This